首页> 外文OA文献 >PCV64 INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL

【2h】

PCV64 INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL

机译：接受冠脉介入治疗的急性冠状动脉综合征患者行PCV64指数，随访和总住院费用的冠脉介入治疗。 TRITON-TIMI 38试验中的氯吡格雷

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Mahoney EM; Wang K; Lei Y; Arnold SV; McCollam PL; Riesmeyer J; Plat F; Cohen DJ;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. [J] . Mahoney EM, Wang K, Arnold S Circulation: An Official Journal of the American Heart Association . 2010,第1期

机译：普拉格雷与氯吡格雷在急性冠状动脉综合征和计划的经皮冠状动脉介入治疗中的成本效益：该试验的结果是通过优化普拉格雷-溶栓治疗心肌梗死TRITON-TIMI 38对血小板的抑制作用来评估治疗效果的改善。
2. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Throm [J] . Antman EM, Wiviott SD, Murphy SA, Journal of the American College of Cardiology . 2008,第21期

机译：普拉格雷在接受经皮冠状动脉介入治疗的急性冠脉综合征患者中的早期和晚期获益：TRITON-TIMI 38（尝试通过普拉格雷-血栓优化血小板抑制剂来评估治疗效果的改善试验）
3. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. [J] . ODonoghue M, Antman EM, Braunwald E Journal of the American College of Cardiology . 2009,第8期

机译：有或无糖蛋白IIb / IIIa抑制剂的普拉格雷在经皮介入治疗的急性冠状动脉综合征患者中的疗效和安全性：TRITON-TIMI 38（通过优化普拉格雷-溶栓治疗对血小板的抑制作用来评估心肌梗塞治疗效果的改善试验38 ）分析。
4. Influence of Diabetes Mellitus in patients with Long Coronary Lesions Undergoing Percutaneous Coronary Interventions: Multicenter PCI Registry in Japan [C] . E. Saito, M. Hirose, T. Miyauchi, International Congress on Coronary Artery Disease . 2003

机译：经皮冠状动脉干预患者糖尿病患者糖尿病的影响：日本多中心PCI登记处
5. The Association between Unfractionated Heparin and Bivalirudin Used during Percutaneous Coronary Intervention for Stable Angina and Acute Coronary Syndromes and the In-Hospital and Mortality Outcomes Observed across All Body Mass Index Groups [D] . Chen, Christine. 2021

机译：在所有体重指数群体中观察到稳定冠状动脉干预期间使用经皮冠状动脉介入和急性冠状动脉综合征的冠状动脉介入和医院和死亡率结果之间的联合肝素和Bivalirudin之间的关联
6. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel [O] . Tobias Geisler, Jean Booth, Elli Tavlaki, -1

机译：经皮冠状动脉介入治疗的急性冠脉综合征患者的高血小板反应性：普拉格雷和氯吡格雷比较的随机对照试验
7. PCV42 HOSPITALIZATION COSTS IN SOUTH KOREA FOR PATIENTS WITHOUT IDENTIFIED RISK FACTORS FOR BLEEDING WHO HAVE ACUTE CORONARY SYNDROMES WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL [O] . Mahoney E, Wang K, Yang BM, 2010

机译：在没有明确危险因素的患者中，韩国的PCV42医院住院费用是谁经急性冠状动脉综合征加经皮冠状动脉介入治疗进行冠状动脉介入治疗后才发现的。 TRITON-TIMI 38试验中的氯吡格雷

PCV64 INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL

著录项

引文网络

相似文献

相关主题

期刊订阅